Logo

Qiagen To Market HLA Typing Technology from Genome Diagnostics

Oct 10, 2006
NEW YORK (GenomeWeb News) – Qiagen secured commercial rights to sell reagents and software for Genome Diagnostics' sequencing based typing technology, Genome Diagnostics said yesterday.
 
The Dutch company has developed a proprietary strategy for typing human leukocyte antigen genes. Qiagen will have global distribution rights to the technology as of January 2007.
 
Qiagen already has an exclusive sales and distribution agreement to distribute with Olerup SSP's HLA sequence specific primer technology for HLA typing, Genome Diagnostics said. With this agreement, Qiagen can offer both products to researchers for a complete HLA typing solution.
 

Financial details were not disclosed.

Breaking News
The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.